证券代码：300122 证券简称：智飞生物 公告编号：2025-54 重庆智飞生物制品股份有限公司 | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | 一种免疫佐剂质 量差异的检测方 | ZL202310716954.1 | 第 8303195 号 | 发明专利 | 2023 年 06 月 | 2025 年 09 月 | 智飞生物 智飞绿竹 | | | | | | 15 日 | 26 日 | | | 法 | | | | | | 智飞龙科马 | 上述发明专利是在公司自主研发且尚处于在研阶段的冻干重组结核疫苗 （AEC/BC02）的研发过程中申请获得。该专利证书的取得不会对公司近期生产经 营产生重大影响，但有利于进一步完善公司知识产权保护体系，充分发挥自主知 识产权优势，促进技术创新，提升公司的核心竞争力。 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 9 月 29 日 1 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确 ...

Core Insights - The company, Zhifei Biological, announced on September 26 that it has gained control of Chanan Biological through a capital increase, expanding its business from vaccines to the field of metabolic diseases [2] Group 1 - The company has successfully completed a capital increase to acquire a controlling stake in Chanan Biological [2] - This strategic move marks the company's expansion into the metabolic disease sector, diversifying its portfolio beyond vaccines [2]

Core Insights - The company Zhifei Biological (300122) reported that as of September 19, 2025, the number of ordinary shareholders is 135,868 [1] Company Summary - Zhifei Biological has a significant number of ordinary shareholders, indicating a broad base of investor interest and potential engagement [1]

Core Insights - The company is facing significant financial challenges, having reported losses for two consecutive quarters, and is actively working on optimizing its operational strategies to ensure stable development [2] - The company has a diverse product portfolio with 15 products on the market, including vaccines for various infectious diseases and tuberculosis-related diagnostic and therapeutic products [2] - The company is committed to enhancing its research and development capabilities and has established three major research and production bases along with an innovation incubation center [2][3] Group 1: Financial Performance and Strategy - The company has experienced severe losses in the first two quarters of the year and is focusing on deepening its core business and accelerating the launch of self-developed products [2] - The company has established a strategic layout to improve its independent innovation capabilities in the fields of vaccines, tuberculosis biological products, and GLP-1 analogs [2] Group 2: Product Development and Market Promotion - The company’s subsidiary has received clinical trial approval for CA111 injection, and several self-developed vaccines are currently under review for market approval [3] - The company is participating in government-led initiatives to enhance public awareness and willingness to vaccinate through promotional activities [3] Group 3: Risk Management and Industry Confidence - The company is addressing investor concerns regarding accounts receivable, bank loans, and inventory risks by optimizing operational strategies and promoting sales through compliant practices [4] - The company emphasizes the strict management of vaccines by the state to alleviate public concerns about vaccine authenticity and to maintain confidence in the industry [4]

Group 1: Financial Performance and Challenges - The company has experienced continuous losses for two consecutive quarters, prompting discussions on response strategies by the management team [2][4]. - In 2024, the company reported a 56% decline in profits, with a further drop of nearly 20% in 2025 [6]. - The company’s accounts receivable, bank loans, and inventory each stand around 20 billion RMB, raising concerns about potential risks of stock delisting [4][6]. Group 2: Product Development and Market Strategy - The company has a total of 15 products on the market, including vaccines for various infectious diseases and diagnostic solutions for tuberculosis [2][3]. - The CA111 injection has received clinical trial approval, with the company committed to timely information disclosure regarding its development [3]. - The company is transitioning from a "super agent" to an innovative vaccine enterprise driven by both research and market strategies [5][6]. Group 3: Marketing and Public Engagement - The company is actively participating in government initiatives to enhance public awareness of disease prevention, which is expected to improve vaccination rates [4][6]. - The company has implemented promotional activities, such as "one injection free" campaigns, to boost public engagement and inventory turnover [6][7]. - The company is focusing on enhancing its marketing strategies to address public concerns regarding vaccine authenticity [4][5]. Group 4: International Expansion and Collaborations - The company is exporting vaccines to countries like Indonesia and Uzbekistan, with ongoing registration processes in the Philippines [7][8]. - The company is preparing for international clinical work on innovative products to expand the global influence of Chinese vaccines [8].

Core Insights - The Chengdu-Chongqing economic circle has seen its GDP grow from less than 6.3 trillion yuan in 2019 to 8.7 trillion yuan in 2024, marking an increase in its share of the national economy from 6.3% to 6.5% [1] - The brand value of listed companies in the Chengdu-Chongqing region has significantly increased, with Wuliangye and Luzhou Laojiao leading the rankings [2][3] Company Insights - Wuliangye (000858.SZ) ranks first with a brand value of 305.96 billion yuan, followed by Luzhou Laojiao (000568.SZ) at 107.67 billion yuan, and Changan Automobile (000625.SZ) at 84.56 billion yuan [2][3] - The beverage industry in the Chengdu-Chongqing region has seen a brand value increase of 117.02 billion yuan over the past four years, making it the highest among all industries [6][8] Industry Insights - The automotive industry in the region has surpassed a brand value of 100 billion yuan, reaching 123.15 billion yuan in 2025 [6][8] - The equipment industry has doubled the number of listed companies over the past four years, indicating a significant growth in this sector [8][10] - The agricultural sector has experienced a decline in brand value, primarily due to the shift of Tongwei Co., Ltd. (600438.SH) from agriculture to the equipment sector [6][8] Regional Insights - Chengdu has the highest increase in both the total brand value of listed companies and the number of companies listed over the past four years [4][5] - The Chengdu-Chongqing region serves as a strategic support for the Yangtze River Economic Belt and is a key demonstration area for the country's new urbanization efforts [2]

Core Insights - On September 24, Zhifei Biological experienced a 0.61% increase in stock price with a trading volume of 446 million yuan [1] - The company reported a net financing purchase of 3.29 million yuan on the same day, with a total financing and securities balance of 1.59 billion yuan [1] Financing Summary - On September 24, Zhifei Biological had a financing purchase of 66.16 million yuan, with a current financing balance of 1.58 billion yuan, representing 3.11% of its market capitalization [1] - The financing balance is above the 60th percentile of the past year, indicating a high level of financing activity [1] Securities Lending Summary - On September 24, Zhifei Biological repaid 3,500 shares in securities lending and sold 4,400 shares, amounting to a selling value of 93,700 yuan [1] - The remaining securities lending balance was 167,000 shares, with a total value of 3.56 million yuan, exceeding the 70th percentile of the past year [1] Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is based in Chongqing and specializes in the research, production, and sales of vaccines and biological products [1] - The company's revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1] Shareholder and Financial Performance - As of August 20, the number of shareholders for Zhifei Biological was 139,500, a decrease of 0.28%, while the average circulating shares per person increased by 0.28% to 10,139 shares [2] - For the first half of 2025, the company reported a revenue of 4.919 billion yuan, a year-on-year decrease of 73.06%, and a net profit of -597 million yuan, a decrease of 126.72% [2] - Cumulatively, the company has distributed 7.318 billion yuan in dividends since its A-share listing, with 3.194 billion yuan in the last three years [2] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder with 36.35 million shares, a decrease of 10.59 million shares from the previous period [2] - E Fund's ChiNext ETF and Huatai-PB's CSI 300 ETF were among the top shareholders, with varying changes in their holdings [2]

特别声明：以上文章内容仅代表作者本人观点，不代表新浪网观点或立场。如有关于作品内容、版权或其它问 题请于作品发表后的30日内与新浪网联系。 一家生物制药企业的日常，如何与亿万人的健康息息相关？早晨9点的实验室，正在发生什么？下午4点 的生产线，又如何运转？环球网独家纪实《智飞一日》，用镜头为您揭秘生物制药企业背后的科技创新 与人性温度。 环球网独家纪实智飞一日揭秘生物制药企业科技创新 环球网独家纪实智飞一日揭秘生物制药企业科 技创新 ...

Core Viewpoint - Zhifei Biological, once thriving on the agency of Merck's HPV vaccine, is now facing multiple challenges including high inventory, difficult receivables, and transformation issues, resulting in its worst interim performance since its listing in 2010 [2][3]. Financial Performance - In the first half of 2025, Zhifei Biological reported revenue of 4.919 billion yuan, a year-on-year decline of 73.06%. The net profit attributable to shareholders was a loss of 599 million yuan, a year-on-year decrease of 126.72%, marking the first half-year loss since the company's listing [3][5]. - The company has been in a continuous loss state for four consecutive quarters [5]. Business Model Challenges - The "agency + self-developed" business model has revealed several risks amid industry fluctuations. The agency business is heavily reliant on upstream suppliers, and any changes in their strategies can directly impact performance. Additionally, the long development cycle and high investment in self-developed products pose risks of product shortages if new products are not timely launched [7]. - Balancing agency introduction and self-development is crucial for domestic vaccine companies. While agency business can quickly enrich the product line, it is essential to choose products with market potential and technological advantages [7]. Dependency on HPV Vaccine - Zhifei Biological's business is highly dependent on the agency of Merck's HPV vaccine, which contributed approximately 68% of revenue in 2024. The company faces two core challenges: increasing channel conflicts as international manufacturers collaborate directly with local firms, and relatively low contribution from self-developed products, which accounts for less than 20% of revenue [8]. Decline in Product Sales - In the first half of 2025, the batch issuance volume of core agency products significantly declined, particularly the four-valent HPV vaccine, which dropped from 466,000 units in the first half of 2024 to 0 units, a decrease of 100%. The nine-valent HPV vaccine issuance fell from 18.272 million units to 4.239 million units, a decline of 76.8% [10][11]. - The revenue from agency products halved, decreasing from 51.89 billion yuan in 2023 to 24.67 billion yuan in 2024, and further down to 4.37 billion yuan in the first half of 2025, a year-on-year decrease of 75.2% [12]. Self-Developed Products - Self-developed product revenue in the first half of 2025 was 500 million yuan, accounting for 10.15% of total revenue, with a gross margin of 78.50%, although this was an 8.06 percentage point decline year-on-year [14]. - The batch issuance volume of self-developed products like ACYW135 and Hib vaccines saw significant declines, with Hib vaccine issuance down 66.46% year-on-year [15][16]. R&D Investment - The company has historically maintained a low R&D expense ratio, below 4%, compared to peers. Although the R&D expense ratio reached 8.5% in the first half of 2025, this was primarily due to a significant drop in revenue [17]. - The projected annual R&D investment for 2025 is approximately 1.27 billion yuan, which is less than the previous year's 1.391 billion yuan [17].

Core Viewpoint - The article highlights the daily operations of a biopharmaceutical company, emphasizing its significant impact on global health and the dedication of its workforce in the pursuit of medical innovation and human well-being [1] Group 1: Company Operations - The article provides a glimpse into the daily activities at the company's research and production bases located in Chongqing, Hefei, and Beijing [1] - It showcases the morning laboratory activities and the afternoon production line operations, illustrating the seamless integration of research and manufacturing processes [1] Group 2: Innovation and Commitment - The narrative emphasizes the technological innovations driving the biopharmaceutical industry and the human element involved in the mission to enhance public health [1] - It pays tribute to the individuals who contribute to the company's efforts in improving health outcomes for millions [1]